SonoThera Secures $125 Million in Latest Series B Funding Round

SonoThera secured $125 million in its latest Series B, adding another data point to the Healthcare & Life Sciences funding market.

SonoThera Raises $125 million in Funding

SonoThera bags $125M series B to advance safer gene therapies. The deal aims to advance safer gene therapies.

Investors Behind the Funding

The round was backed by undisclosed investors. Funding Intelligence tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

SonoThera operates in Healthcare & Life Sciences. SonoThera bags $125M series B to advance safer gene therapies's Series B round shows investors are still backing digital health platforms with real scale narratives. At $125M, the deal suggests buyers want category leaders that can turn AI, automation, or workflow leverage into durable enterprise demand.

Strategic Use of Funds

SonoThera bags $125M series B to advance safer gene therapies operates as a Digital Health company. The transaction supports efforts to advance safer gene therapies.

Looking Ahead

SonoThera bags $125M series B to advance safer gene therapies

Source reference: original announcement/article.